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The synthesis of mitozolomide was reported by Stevens et al.
(1984) and pre-clinical trials have indicated that it possesses
cytotoxic activity against a number of animal tumours
(Hickman et al., 1985). Phase II clinical studies have shown
moderate antitumour activity (Gunderson et al., 1987), and
an early phase clinical study with autologous bone marrow
rescue is in progress at Wellington Hospital. In the
Wellington Hospital study one patient underwent a course of
radiotherapy following treatment with mitozolomide. The
patient had a urethral carcinoma which did not respond to
mitozolomide, but after radiotherapy the lesion regressed
dramatically. This chance observation led us to consider the
possibility that mitozolomide had acted as a radiation
sensitiser.
It has been suggested that mitozolomide cytotoxicity is
due to DNA interstrand cross-linkage, following alkylation
of guanine bases (Gibson et al., 1984a,b). In this respect
mitozolomide appears similar to BCNU (1,3 bis (2-
chloroethyl)-l-nitrosourea) and other nitrosoureas (Kohn,
1977). Radiation can enhance interstrand cross-linking by
BCNU (Tofilon et al., 1984). Cross-linking agents have also
been found to enhance radiation-induced cell killing in
mammalian cells in vitro (Nias, 1985; Wheeler et al., 1977)
and the combination can be more effective in vivo than the
single agents (Barker et al., 1979; Walker & Gehan, 1976).
We have therefore investigated the hypothesis that
mitozolomide enhances radiation damage using mammalian
cells in vitro. Chinese hamster ovary (AA8 sub-line) cells
were maintained at 37°C as monolayer cultures in minimal
essential medium (alpha-modification) with 10% fetal calf
serum and without added antibiotics. Sub-culture was
carried out bi-weekly. Once cells in late log phase had been
trypsinised for use in experiments the fetal calf serum was
reduced to 5% and penicillin (100pgml-1) and streptomycin
(100#gml-1) added. This latter medium was also used to
plate out and incubate the cells.
Mitozolomide was provided by Rhone Poulenc (NZ) Ltd
and made up just prior to use by dissolving the powder in
dimethylsulphoxide and subsequent dilution into growth
medium. The maximum dimethylsulphoxide concentration in
the cultures (0.7% v/v) had no effect on cell viability. Cells
were exposed to the drug for 1 h, usually by careful addition
of the drug to the monolayer cultures. However, in a few
experiments the drug was added to cells in suspension. Drug
toxicity was similar in monolayer and suspension culture.
After drug exposure the medium was removed and the
cells rinsed with medium and either trypsinised immediately
or re-incubated with fresh, drug-free medium for a given
period before trypsinisation. The cells were centrifuged and
resuspended at about 106 cells ml -I in the complete medium.
After 20min re-equilibration at 37°C in an atmosphere of
5% CO2 95% air, the cells were irradiated in small
stoppered glass vessels. The irradiation source (AECL,
Gammacell 220) provided a gamma-ray dose rate of about
7Gymin-1.
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Standard methods were used to dilute, plate, incubate and
count the surviving cells. Each data point was obtained from
triplicate plates and experiments were repeated independently
2-4 times. Untreated cells and cells exposed to drug alone
were used as controls in each experiment. The plating
efficiency (the number of colonies observed/number of cells
plated) was calculated for untreated cells (PE,), and for cells
treated by radiation alone (PER), drug alone (PED) or drug
plus radiation combinations (PED+R).
The fraction of cells surviving treatment with drug,
radiation or the combination could be obtained by PED/PEC,
PER/PEC or PED+R/PE. respectively. Experiments were
designed principally to test the effect of drug exposure on
the radiation response. Therefore the surviving fraction in
combination experiments was corrected for the cell killing
introduced by the drug alone. Calculation of PED+R/PED
yielded the fraction of cells surviving the irradiation in
combination experiments for comparison with the results of
true radiation-only experiments.
Radiation survival curves were obtained from the data by
applying the linear-quadratic equation
-log,S= ocD+PD2, [1]
where S is the fractional survival after a dose D, and oc and
( are the fitted coefficients.
Untreated AA8 cells routinely had a plating efficiency,
PEC, in the range 0.75-0.90. The toxicity of a I h treatment
with mitozolomide in the concentration range 30-
50#moldm3 reduced the fraction of viable cells to 0.4-0.15.
Figure 1 indicates that when irradiated 8h later the cells
surviving the drug treatment were more sensitive to radiation
than non-treated controls (P<0.005).
Lower concentrations had a greatly reduced toxic effect.
Mitozolomide at 10 umoldm-3 resulted in a surviving
fraction of about 0.8 and 8h later did not produce any
radiosensitisation of the cells which survived the drug
treatment (P>0.3).
The enhancing effect of the drug was measured by the
ratio of doses required to achieve a given surviving fraction
in control and drug-treated cells. This enhancement ratio
(ER) is 1.25 +0.04 throughout the survival range 0.2-0.001
for the curves in Figure 1 fitted by equation [1]. Thus
mitozolomide pre-treatment appears to act as a simple dose
modifying agent.
The importance of the scheduling of the drug and
radiation treatments was also investigated (Figure 2).
Enhancement was observed when the radiation exposure
followed drug treatment by 4-12h. Longer or shorter delays
before irradiation resulted in almost no enhancement. The
comparatively greater error bars at 4h in Figure 2 reflect the
greater variation in the degree of enhancement found at this
time. Separate experiments showed that allowing
mitozolomide to remain in contact with the cells during the
irradiation had no effect on the radiation response.
A number of explanations for our results are possible. In
view of the need for toxic drug concentrations and the
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Figure 1 The radiation response of control AA8 cells (-l) and
cells treated for 1 h with 30umoldm3 (0) or 50 umoldm-3 (0)
mitozolomide. Irradiation was performed in air at room
temperature 8h after completion of drug treatment. The
standard error of the mean individual points was almost always
within the size of the points. There was no significant difference
between the data obtained with the two drug concentrations. The
data for drug-treated cells (five separate experiments in total)
were therefore pooled and fitted to equation [1]. Values (with
standard deviations) for drug-treated cells were a=0.316 (0.0297)
Gy-1 and /,=0.0300 (0.00308) Gy-2. Values for control cells
were a=0.208 (0.0242) Gy-1, /3=0.0246 (0.00234) Gy-2. The
error bars on the fitted curves represent the 95% confidence
intervals for the fit.
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Horgan et al. (1983) have reported briefly on a flow
cytometric analysis of mitozolomide-treated cells.
Mitozolomide under conditions described as minimally toxic
depleted the G1 cell fraction and produced a block in the cell
cycle at G2/M. Broggini et al. (1986) reported similar results
with mitozolomide treatment of tumour-bearing mice
(10mgkg-1). Cell cycle effects less than 24h after treatment
were not examined, but appeared to peak about 48h after
treatment. Although the experimental conditions differed
from ours, the flow cytometry results lend some support to
an explanation of our results based on cell cycle effects.
However, the results of Broggini et al. (1986) indicate that
the time course of radiosensitisation may differ from cell
cycle effects.
Gibson et al. (1984a,b) noted that maximum DNA cross-
linkage occurred some 12h after mitozolomide treatment of
a transformed cell line. This is near the peak of the period in
which radiation enhancement occurred. It is not possible at
present to tell whether this is a coincidental finding or an
indication that DNA cross-linking and radiation
enhancement are directly related. However, a normal cell
line, which was proficient in repair of the initial guanine
adducts, demonstrated little cross-linking.
Another possible explanation is that mitozolomide
interferes with the accumulation or repair of sub-lethal or
potentially lethal damage. This was the explanation
tentatively favoured for the enhancement brought about by
BCNU in rat 9L brain tumour cells in vitro (Wheeler et al.,
1977). Since BCNU is thought to have similarities with
mitozolomide in its cytotoxic mode of action (Gibson et al.,
1984a; Horgan & Tisdale, 1984), a similar explanation for
mitozolomide should be considered. The maximum
enhancement by BCNU at surviving fractions of 0.1 or less
is similar to the enhancement by mitozolomide, and this
maximum effect also occurred some 5-15h after BCNU
treatment.
However, the differences between the two drugs are even
more notable. BCNU provided enhancement at relatively
non-toxic concentrations and with a far wider range of
schedules than found with mitozolomide, including
simultaneous treatments and irradiation before drug
treatment. The principal effect of BCNU, seen with all
schedules, was to reduce the shoulder on the radiation
survival curve, whereas enhancement by mitozolomide was
reasonably constant throughout the dose range.
Phase 1 trials of mitozolomide have indicated peak plasma
levels in the approximate range 1-10mgl-1 at tolerable
doses (M.J. McKeage, unpublished observations; Newlands
et al., 1985). Peak tumour levels of 3-15mgkg-1 have been
reported in an animal tumour (Broggini et al., 1986). These
values may be compared with media concentrations of 30-
50#moldm-3 or 7-12mg1-1 at which radiosensitisation was
0 5 10 15 20 25 observed.
We conclude that mitozolomide has the potential to
Hoursbefore irradiation enhance radiation damage, and this should be borne in mind
pendence of the enhancement ratio (ER) upon for radiotherapy patients likely to undergo a concurrent
een drug and radiation treatments. Data are course of mitozolomide. However, our present results suggest
e mean and range of values in two or more that any effect will be modest and be maximal at about 12h
nts. after drug treatment. Effects could be comparable to any
produced by BCNU. In the clinically relevant radiation dose
1 hours before enhancement was observed, range, however, it is more likely that mitozolomide would be
nation is thatn the drug treatment altered less effective than BCNU since the latter is particularly
d progression of cells within the cell cycle effective in the low dose region and at ' non-toxic
12 h after treatment the cells destined to concentrations. The excellent response of a patient to
exposure are presumed to be distributed radiotherapy following a course of mitozolomide occurred
11 cycle stages so as to be more sensitive to with a gap of several days between drug and radiation
the original asynchronous population. treatments and was probably a chance finding.
n;+~~~at ,_ ... J.,t .....I I :r+1 isitvlty to raulauton at aitterent cell cycle
established (Terasima & Tolmach, 1963;
on, 1966). The results indicate that the
11 cycle distribution important to overall
ty occur with drug concentrations between
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